Product Information
TRILEPTAL 300 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $10.4559 per EA under NDC 00078033705. Its NADAC has been published 644 times since Nov 28, 2013.
FDA first approved this application on Jan 14, 2000. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the oxcarbazepine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078033705
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
OXCARBAZEPINEApproval Type
New Drug (NDA)
FDA Application
NDA021014FDA Approved
1/14/2000
TE Code
AB
On Market Since
1/30/2000
Pharmacological Classes
Price Statistics
The NADAC for TRILEPTAL 300 MG TABLET has been published 644 times since Nov 28, 2013, and over the history we have for it it has risen 145.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.4559 per EA |
|---|---|
| All-time high | $10.4800 (May 13, 2026) |
| All-time low | $4.2118 (Dec 18, 2013) |
| 52-week high | $10.4800 |
| 52-week low | $10.1583 |
| Median price | $8.3496 |
| Average price | $8.0569 |
| Largest weekly change | +14.9% (Jan 14, 2015) |
| Weeks tracked | 644 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 98% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of TRILEPTAL 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRILEPTAL 300 MG TABLET, manufactured by Novartis Pharmaceuticals Corporation, is $10.4559 per EA (NDC 00078033705), effective Aug 19, 2026.
How has the price of TRILEPTAL 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for TRILEPTAL 300 MG TABLET has risen 145.5%. It has been tracked across 644 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRILEPTAL 300 MG TABLET?
Since Nov 28, 2013, the NADAC for TRILEPTAL 300 MG TABLET has ranged from a low of $4.2118 (Dec 18, 2013) to a high of $10.4800 (May 13, 2026), with a median of $8.3496 per EA.
Are there cheaper alternatives to TRILEPTAL 300 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OXCARBAZEPINE 300 MG TABLET, is $0.1637 per EA — about 98% below TRILEPTAL 300 MG TABLET.
Who manufactures TRILEPTAL 300 MG TABLET?
TRILEPTAL 300 MG TABLET (NDC 00078033705) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.